Journal of Medicinal Chemistry CH3). 13C NMR (DMSO-d6): δ 152.7, 139.9, 134.9, 128.8, 128.7, 126.2, 126.0, 125.7, 112.6, 112.3, 23.1, 14.4. 4-Amino-N-(2-propylphenyl)benzenesulfonamide (91). Yield, 77%; orange solid; mp, 153−154 °C. IR ν: 3475 (NH2), 3379 (NH2) cm−1. 1H NMR (CDCl3/MeOD): δ 7.05−6.66 (m, 8H, Ar), 6.27 (brs, 2H, NH2), 2.08 (t, 2H, J = 7.8 Hz, CH2), 1.13−1.03 (m, 2H, CH2), 0.53 (t, 3H, J = 7.3 Hz, CH3). 13C NMR (DMSO-d6): δ 154.2, 152.7, 138.3, 135.1, 130.6, 129.5, 128.6, 126.1, 125.9, 125.7, 112.6, 112.3, 32.3, 22.9, 14.0. ■ ■ ■ ■ AUTHOR INFORMATION Corresponding Author *For S.F.: phone, 418-525-4444, extension 52364; fax, 418-525- 4372; e-mail, sebastien.fortin.81@gmail.com. For R.C.-G.: phone, 418-525-4444, extension 52363; fax, 418-525-4372; e- mail, rene.c-gaudreault@crsfa.ulaval.ca. Notes The authors declare no competing ﬁnancial interest. ACKNOWLEDGMENTS This work was supported by the Canadian Institutes of Health Research (R.C.-G, Grants MOP-79334 and MOP-89707). Work in the Masson laboratory was supported by the CIHR. S.F. is a recipient of a studentship from the Canadian Institutes of Health Research (Grant CGD-83623). We are indebted to Dr. Richard Poulin for his dedicated help and insightful comments of this manuscript. ABBREVIATIONS USED CEU, 2-chloroethylurea; PIB-SO, phenyl 4-(2-oxoimidazolidin- 1-yl)benzenesulfonate; PUB-SO, N-phenyl ureidobenzenesul- fonate; PUB-SA, N-phenylureidobenzenesulfonamide; CPU, 3- c h l o r o p r o p y l u r e a ; E U , e t h y l u r e a ; c D D P , c i s - diamminedichloroplatinum(II) (cisplatin); CA-4, combretasta- tin A-4; CAM, chick chorioallantoic membrane; DMEM, Dulbecco’s minimal essential medium; PBS-T, PBS supple- mented with 0.05% (v/v) Tween 20 REFERENCES (1) Fortin, J. S.; Lacroix, J.; Desjardins, M.; Patenaude, A.; Petitclerc, E.; C.-Gaudreault, R. Alkylation potency and protein speciﬁcity of aromatic urea derivatives and bioisosteres as potential irreversible antagonists of the colchicine-binding site. Bioorg. Med. Chem. 2007, 15, 4456−4469. (2) Fortin, S.; Moreau, E.; Lacroix, J.; Teulade, J. C.; Patenaude, A.; C.-Gaudreault, R. N-Phenyl-N′-(2-chloroethyl)urea analogues of combretastatin A-4: Is the N-phenyl-N′-(2-chloroethyl)urea pharma- cophore mimicking the trimethoxy phenyl moiety? Bioorg. Med. Chem. Lett. 2007, 17, 2000−2004. (3) Fortin, S.; Moreau, E.; Patenaude, A.; Desjardins, M.; Lacroix, J.; Rousseau, J. L.; C.-Gaudreault, R. N-Phenyl-N′-(2-chloroethyl)ureas (CEU) as potential antineoplastic agents. Part 2: Role of ω-hydroxyl group in the covalent binding to β-tubulin. Bioorg. Med. Chem. 2007, 15, 1430−1438. (4) Moreau, E.; Fortin, S.; Desjardins, M.; Rousseau, J. L.; Petitclerc, E.; C.-Gaudreault, R. Optimized N-phenyl-N′-(2-chloroethyl)ureas as potential antineoplastic agents: synthesis and growth inhibition activity. Bioorg. Med. Chem. 2005, 13, 6703−6712. (5) Moreau, E.; Fortin, S.; Lacroix, J.; Patenaude, A.; Rousseau, J. L.; C.-Gaudreault, R. N-Phenyl-N′-(2-chloroethyl)ureas (CEUs) as potential antineoplastic agents. Part 3: Role of carbonyl groups in the covalent binding to the colchicine-binding site. Bioorg. Med. Chem. 2008, 16, 1206−1217. (6) Mounetou, E.; Legault, J.; Lacroix, J.; C.-Gaudreault, R. Antimitotic antitumor agents: synthesis, structure−activity relation- Article ships, and biological characterization of N-aryl-N′-(2-chloroethyl)ureas as new selective alkylating agents. J. Med. Chem. 2001, 44, 694−702. (7) Mounetou, E.; Legault, J.; Lacroix, J.; C.-Gaudreault, R. A new generation of N-aryl-N′-(1-alkyl-2-chloroethyl)ureas as microtubule disrupters: synthesis, antiproliferative activity, and β-tubulin alkylation kinetics. J. Med. Chem. 2003, 46, 5055−5063. (8) Fortin, J. S.; Cote, M. F.; Lacroix, J.; Desjardins, M.; Petitclerc, E.; C.-Gaudreault, R. Selective alkylation of βII-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents. Bioorg. Med. Chem. 2008, 16, 7277−7290. (9) Fortin, J. S.; Cote, M. F.; Lacroix, J.; Patenaude, A.; Petitclerc, E.; C.-Gaudreault, R. Cycloalkyl-substituted aryl chloroethylureas inhibit- ing cell cycle progression in G0/G1 phase and thioredoxin-1 nuclear translocation. Bioorg. Med. Chem. Lett. 2008, 18, 3526−3531. (10) Fortin, J. S.; Cote, M. F.; Lacroix, J.; Petitclerc, E.; C.- Gaudreault, R. Aromatic 2-chloroethyl urea derivatives and bio- isosteres. Part 2: Cytocidal activity and eﬀects on the nuclear translocation of thioredoxin-1, and the cell cycle progression. Bioorg. Med. Chem. 2008, 16, 7477−7488. (11) Bouchon, B.; Papon, J.; Communal, Y.; Madelmont, J. C.; Degoul, F. Alkylation of prohibitin by cyclohexylphenyl-chloroethyl urea on an aspartyl residue is associated with cell cycle G1 arrest in B16 cells. Br. J. Pharmacol. 2007, 152, 449−455. (12) Patenaude, A.; Deschesnes, R. G.; Rousseau, J. L.; Petitclerc, E.; Lacroix, J.; Cote, M. F.; C.-Gaudreault, R. New soft alkylating agents with enhanced cytotoxicity against cancer cells resistant to chemo- therapeutics and hypoxia. Cancer Res. 2007, 67, 2306−2316. (13) Bouchon, B.; Chambon, C.; Mounetou, E.; Papon, J.; Miot- Noirault, E.; C.-Gaudreault, R.; Madelmont, J. C.; Degoul, F. Alkylation of β-tubulin on Glu 198 by a microtubule disrupter. Mol. Pharmacol. 2005, 68, 1415−1422. (14) Fortin, S.; Wei, L.; Moreau, E.; Labrie, P.; Petitclerc, E.; Kotra, L. P.; C.-Gaudreault, R. Mechanism of action of N-phenyl-N′-(2- chloroethyl)ureas in the colchicine-binding site at the interface between α- and β-tubulin. Bioorg. Med. Chem. 2009, 17, 3690−3697. (15) Wiesen, K. M.; Xia, S.; Yang, C. P.; Horwitz, S. B. Wild-type class I β-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a β-tubulin mutation. Cancer Lett. 2007, 257, 227−235. (16) Fortin, S.; Wei, L.; Moreau, E.; Lacroix, J.; Cote, M. F.; Petitclerc, E.; Kotra, L. P.; C.-Gaudreault, R. Design, synthesis, biological evaluation, and structure−activity relationships of sub- stituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4. J. Med. Chem. 2011, 54, 4559−4580. (17) Screening Services. NCI-60 DTP Human Tumor Cell Line Screen. http://dtp.nci.nih.gov/branches/btb/ivclsp.html (accessed September 25, 2011). (18) Paull, T. T.; Rogakou, E. P.; Yamazaki, V.; Kirchgessner, C. U.; Gellert, M.; Bonner, W. M. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr. Biol. 2000, 10, 886−895. (19) Ivashkevich, A. N.; Martin, O. A.; Smith, A. J.; Redon, C. E.; Bonner, W. M.; Martin, R. F.; Lobachevsky, P. N. γH2AX foci as a measure of DNA damage: a computational approach to automatic analysis. Mutat. Res., Fundam. Mol. Mech. Mutagen. 2011, 711, 49−60. (20) Bonner, W. M.; Redon, C. E.; Dickey, J. S.; Nakamura, A. J.; Sedelnikova, O. A.; Solier, S.; Pommier, Y. γH2AX and cancer. Nat. Rev. Cancer. 2008, 8, 957−967. (21) Rogakou, E. P.; Pilch, D. R.; Orr, A. H.; Ivanova, V. S.; Bonner, W. M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 1998, 273, 5858−5868. (22) Rogakou, E. P.; Nieves-Neira, W.; Boon, C.; Pommier, Y.; Bonner, W. M. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J. Biol. Chem. 2000, 275, 9390−9395. (23) Rodrigue, A.; Lafrance, M.; Gauthier, M. C.; McDonald, D.; Hendzel, M.; West, S. C.; Jasin, M.; Masson, J. Y. Interplay between 6207 dx.doi.org/10.1021/jm3006492 | J. Med. Chem. 2012, 55, 6194−6208